AC
AC Immune S.A.
ACIU · NASDAQ
$2.73 -3.02% (-$0.09)
1M -1.80%
Market Cap CHF 229.7M
P/E Ratio -
Div. Yield -
ROE 99.17%
Bulios Fair Price
$3.74
37.2% upside
Current Price
$2.73
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ACIU is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
9 /100
Expensive P/B 6.53x
P/S 13.12x
EV/FFO N/A
Growth
3 /100
Declining Book val. growth 35.70%
Rev. growth 3.17%
FCF growth N/A
Profitability
20 /100
Weak Net margin 246.49%
Op. margin 252.25%
FCF margin 199.63%
Quality
2 /100
Poor ROE 99.17%
ROA 28.70%
Asset turnover 0.12x
Debt
54 /100
Moderate Current ratio 0.93x
Int. coverage -256.38x
Debt/Equity 0.12x
Stability
25 /100
Unstable Rev. volatility 181.62%
EPS volatility 34.57%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ACIU
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Martin Zügel
Employees
106
Headquarters
Lausanne
Upcoming events
03 NOV
Earnings
Upcoming earnings report